Insights
Insights From Our Experts
Articles
Clinical Pathways and Policy to Guard Against Misaligned Incentives
Posted by
Seth Gordon , Dr. Richard Stefanacci on April 29, 20204/29/20
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
COVID-19 Payer Pulse Research Summary
Posted on April 29, 20204/29/20
The current public health pandemic is impacting healthcare stakeholders from doctors and nurses in the frontline to payers and PBMs. EVERSANA is monitoring the constant changes to access and benefit consideration tracking payer responses and key…
ACCESSEXPRESS® by EVERSANA Payer Coverage and Reimbursement Case Study
ACCESSEXPRESS allows you to have full control of the survey process getting answers to your most pressing business questions within hours. See how our client used our research platform to assess payer coverage and reimbursement for…
[Infographic] Defining the Digital Space
Posted on April 27, 20204/27/20
Despite the increased popularity of Digital Therapeutics and Digital Medicines, there is still ambiguity around their definitions. This infographic provides clarity and defines the Digital Healthcare Space. Digital Therapeutics (DTx) Evidence-based digital solutions making direct therapeutic…
What is Your Data Integration and Analytics Platform Strategy?
Posted on April 22, 20204/22/20
If I Could Only Ask Two Questions, the First One Would Be: What is Your Data Integration and Analytics Platform Strategy? It’s really simple, data analytics drives decisions. In the healthcare industry, we use data to…
Oncology Market: Outlook of Brand Access and Insights
The oncology market is constantly changing and EVERSANA continues to assess current and future market trends, payer willingness to pay and the optimal patient support services to ensure you have all the insights you need to…
What does the new FDA Guidance for DTx Products Treating Psychiatric Disorders actually mean?
On April 14, 2020, FDA posted new guidance that eases regulatory enforcement of Digital Therapeutics to improve patient access to psychiatric care during the COVID-19 public health emergency. FDA should be praised for this decision, as…
What kind of clinical data is required for FDA clearance of a Digital Medicine?
What kind of clinical data is required for FDA clearance of a Digital Medicine? It depends. Digital therapeutics and digital medicines that are subject to FDA regulation are considered medical devices. The amount of clinical data…
What specifically triggers FDA regulation of a digital medicine?
I often meet with Digital Health or Pharmaceutical clients to discuss their commercialization journey, and they ask me the same question. What specifically triggers FDA regulation of a digital medicine? Some of these products require FDA…
A Patient Hero
Making the Patient an Extension of the Team The concept of patient-centricity is well embedded throughout EVERSANA and is intrinsically tied to helping the agency’s clients achieve their goals. Kristin LaBounty Phillips believes that the entire…